🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Stellar neoadjuvant/adjuvant clinical trials session today #AACR25 AACR chaired by Aparna Raj Parikh! Dr. Bishoy M. Faltas presented #CLONEVO trial, neoadjuvant abemaciclib for cis-ineligible #bladdercancer - we participated UTSW Simmons Cancer Center led by Suzanne Cole, MD, FACP, FASCO!

Why is there a difference in the pCR from NIAGARA at #ASCOGU25 Matt Galsky & #AUA25 Joshua Meeks (37% vs 42% for chemo/durva)? The 37% includes all ITT patients while the 42% only has surgery pts. Variability in pCR reporting is widespread making cross trial comparison hazardous.⚠️

We tested the feasibility and immunogenicity of a personalized neoantigen vaccine + PD-L1 blockade in #bladdercancer including the adjuvant setting. nature.com/articles/s4301… Jon Anker, MD, PhD Bhardwaj Lab UroToday.com Uromigos The Tisch Cancer Institute Dr. Bishoy M. Faltas Nature Cancer Bladder Cancer Advocacy Network

JUST IN/Big news for #bladdercancer: PDL1 inhibitor Durvalumab regimen demonstrated improvement in DFS for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial. News from AstraZeneca this morning! Bladder Cancer Advocacy Network Dana-Farber Lank Center for Genitourinary Oncology astrazeneca.com/media-centre/p…

Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial OUT ON nature Cancer nature.com/articles/s4301… Study evaluated the feasibility and safety of combining atezolizumab, an anti–PD-L1 immune checkpoint inhibitor, with PGV001, a personalized

Just in case anyone missed this? prnewswire.com/news-releases/… UroToday.com Uromigos Bladder Cancer Advocacy Network

Thrilled to share our new analysis from CheckMate 901! 🟡In N+ only metastatic UC, Nivolumab + chemo doubled complete response rate vs chemo alone (63% vs 34%) and prolonged PFS (HR 0.38) and OS (HR 0.58). ➡️A new horizon for a distinct subgroup. European Urology OncoAlert

Matt Galsky Icahn School of Medicine at Mount Sinai leads Alliance for Clinical Trials in Oncology A032103 (MODERN) to test the role of DNA released from tumor cells into the blood in guiding the use of #immunotherapy after bladder removal for #bladdercancer treatment: bit.ly/Alliance-A0321… @bladdercancerus

Matt Galsky discusses the ctDNA data from NIAGARA presented at #ASCO25. ctDNA positivity is distinct from path CR and ctDNA positive patients do poorly creators.spotify.com/pod/show/the-u…

Important academic study in context of BCG shortage. No definitive benefit for adding mitomycin but ?decreased progression and benefit in patients at highest risk (2 endpoints/subsets). #MedIQASCO25 #ASCO25 #bladdercancer Congrats ANZUP

Our contemporary "negative" RCTs in metastatic UC are just not the same as our "negative" RCTs of the past. Granted a small subset -- but this is durable disease free survival OFF treatment after Ipi + Nivo #CM901. #MedIQASCO25 #ASCO25 #bladdercancer.

Congrats Dr. Bishoy M. Faltas for the CLONEVO study presentation showing us the ctDNA can help distinguish "contribution of components" in WOO studies in MIBC. Another piece of elegant work from his group. #MedIQASCO25 #ASCO25 #bladdercancer

Trying to reconcile the ctDNA detection rates post-RC from NIAGARA versus IMvigor 010 and other datasets...remember IMvigor 010 only included patients with high risk path features (whereas post RC data in NIAGARA includes all ≥ypT0N0). #MedIQASCO25 #ASCO25 #bladdercancer.

Very proud of our own Saad Atiq National Cancer Institute senior fellow presenting data on the Prevalence of Histology-Agnostic Biomarkers in Pure Squamous Cell Carcinomas of the #Bladder showing 1/3 of patients with TMB-High ASCO #ASCO25 Caris Life Sciences

Saxena, Anker, Kodysh et al. demonstrated that the personalized long-peptide neoantigen vaccine PGV001, in combination with atezolizumab, was feasible, safe, and elicited durable neoantigen-specific T cell [...] bit.ly/3T6h5cq  Icahn School of Medicine at Mount Sinai  Julia Kodysh  Matt Galsky

Out in NEJM!! 🚨 Breakthrough in HLRCC-associated RCC! A Phase 2 trial shows that 💉bevacizumab + erlotinib offers high efficacy in advanced papillary renal cell carcinoma: 🔬 HLRCC-associated pRCC: ✅ 72% response rate ⏱️ Median PFS: 21.1 mo 💀 Median OS: 44.6+ mo 🔬 Sporadic

🔬 CONTACT-02 Phase 3 Trial in mCRPC 🔬 📍 Patients with metastatic castration-resistant prostate cancer + extrapelvic soft-tissue mets post-ARPI 💊 Cabozantinib + Atezolizumab vs ARPI switch ✅ PFS: 6.3 vs 4.2 mo (HR 0.65, P=0.0007) ❌ OS: No significant difference (14.8 vs

An excellent review on optimising treatment of stage 2 seminoma. Very well written highlighting the double edge sword - efficacy and toxicity. doi.org/10.1200/OP-25-… Toni Choueiri, MD UroToday.com Jonathan Rosenberg MD Bradley McGregor Karine Tawagi MD Rana McKay, MD, FASCO Matt Galsky Bhardwaj Lab

ctDNA can help guide adjuvant decision making in MIBC In pts with undetectable ctDNA after NAC + cystectomy, no definitive benefit for adjuvant ICB authors.elsevier.com/c/1lMET14kpm0h… Matt Galsky The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai Uromigos Bladder Cancer Advocacy Network UroToday.com World Bladder Cancer Patient Coalition OncLive.com

Should #radicalcystectomy ever be considered for consolidate therapy post EV/P?dailynews.ascopubs.org/do/personalizi… Petros Grivas Shilpa Gupta Tom Powles Matt Galsky Oncology Brothers Sumanta K. Pal, MD, FASCO Yüksel Ürün niraj Ashish M. Kamat, MD, MBBS IBCG SWOG Cancer Research Network Society of Urologic Oncology Bladder Cancer Advocacy Network